Vemurafenib
Clinical Trials Overview
17 trials found
About Vemurafenib
Vemurafenib is an oral selective BRAF kinase inhibitor approved for treating metastatic colorectal cancer harboring the BRAF V600E mutation. This targeted therapy specifically addresses the oncogenic BRAF mutation found in approximately 8-10% of colorectal cancers, often used in combination with other agents like cetuximab or MEK inhibitors. Vemurafenib represents a precision medicine approach for CRC patients whose tumors carry this specific molecular alteration, particularly in cases where standard chemotherapy regimens have failed.
Category
Targeted Therapy
Brand Name
Zelboraf
Mechanism
Vemurafenib selectively inhibits the mutated BRAF V600E protein kinase, which normally drives uncontrolled cell proliferation through constitutive activation of the MAP kinase pathway. By blocking this aberrant BRAF signaling, the drug helps restore normal cell cycle control and promotes cancer cell death in tumors dependent on this oncogenic driver mutation.
Efficacy Data by Mutation
Response rates and survival outcomes by patient molecular profile
BRAF V600E
2B
35%
ORR
4.4m
PFS
9.6m
OS
n=19
Sample
BRAF V600E
2B
4%
ORR
3.7m
PFS
7.1m
OS
n=27
Sample
BRAF V600E
2B
4%
ORR
3.7m
PFS
7.1m
OS
n=27
Sample
BRAF V600E
3
33.3%
ORR
3.5m
PFS
7.2m
OS
n=12
Sample
17
Total Trials
5
Recruiting
2
Active
9
Completed
4,235
Total Enrollment
17
Countries
Research trend for Vemurafenib
Number of trials started per year
Research has declined since peaking at 2 trials in 2013.
Active sites for Vemurafenib
Recruiting sites
17 countries
Phase:
NCT06763029
Phase 2
Recruiting
36 patients
Medications:
Cetuximab
Vemurafenib
Efficacy and safety of irinotecan liposomes combined with cetuximab + vermofenib in first-line failure of advanced RAS wild /BRAF mutated colorectal cancer, Exploratory analysis of biomarkers (including but not limited to ctDNA, immune microenvironme...
China
NCT06603376
Phase 2
Recruiting
75 patients
Based on the upstream signaling features of BRAFV600E and the bypass feedback mechanisms, considering the pro-apoptotic effects of chemotherapy and the synergistic effects of targeted therapy, previous IMPROVEMENT trial creatively explored a balanced...
China
NCT06008119
Phase 3
Recruiting
165 patients
Medications:
Tunlametinib
Vemurafenib
This is a multicenter, randomized, open-label, Phase 3 study
China
NCT05768178
Phase 2
Recruiting
30 patients
Medications:
Cobimetinib
Vemurafenib
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma. Cobimetinib is approved as standard of care in combi...
United Kingdom
NCT05525858
Not Applicable
Recruiting
1,000 patients
Medications:
Alectinib
Atezolizumab
Bevacizumab
Entrectinib
Erlotinib
Pertuzumab
Pralsetinib
Trastuzumab
Vemurafenib
A national, prospective, multi-center, open-label, multi-cohort study comprised of a framework to screen patients for actionable targets and evaluation of molecular profiling guided therapy recommended by MTB based on genomic alterations using target...
South Korea
NCT03155620
Phase 2
Active
1,377 patients
Medications:
Ensartinib
Erdafitinib
Ivosidenib
Olaparib
Palbociclib
Samotolisib
Selpercatinib
Tazemetostat
Tipifarnib
Ulixertinib
Vemurafenib
This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following a...
United States, Australia, Canada, Puerto Rico
NCT02304809
Phase 2
Active
216 patients
Medications:
Vemurafenib
Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment.
To explore the efficacy of vemurafenib as a single a...
France
NCT04831528
Not Applicable
Not yet recruiting
100 patients
This study aimis at detecting the genomic changes of ctDNA in patients of RAS and BRAF wild-type mCRC, who failed after first line treatment containing cetuximab. According to the results of ctDNA detection, individualized second-line targeted therap...
NCT05233332
Phase 2
Completed
Medications:
Vemurafenib
The study consists of the two parts, phase IIa and phase IIb.
China
NCT05019534
Phase 1
Completed
BRAF mutation exists in about 10-12% of colorectal cancer, among which BRAF V600E mutation is the most common type, which is an important biomarker for predicting the prognosis and precise treatment efficacy of metastatic colorectal cancer (mCRC). Th...
China
NCT04790448
Phase 1
Completed
37 patients
This prospective, multicenter, single arm clinical trial was designed to evaluate the efficacy and safety of Vemurafenib in combination with Irinotecan and Cetuximab in the treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer.
China
NCT03727763
Phase 2
Completed
This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.
China
NCT05540951
Phase 3
Completed
In this study, we compared first-line VIC regimen with chemotherapy plus bevacizumab in Chinese patients with initially unresectable BRAF V600E-mutated mCRC. The principal goal was to evaluate the safety of VIC regimen, and to investigate the tumor r...
China
NCT02291289
Phase 2
Completed
1,044 patients
Medications:
5-Fluorouracil
Atezolizumab
Bevacizumab
Capecitabine
Cetuximab
Cobimetinib
Leucovorin
Oxaliplatin
Pertuzumab
Trastuzumab
Vemurafenib
This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have r...
Argentina, Belgium, Bosnia and Herzegovina, Brazil, Denmark, Egypt, France, Germany, Greece, Italy,
NCT02164916
Phase 2
Completed
106 patients
Medications:
Cetuximab
Vemurafenib
This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread to other places in t...
United States
NCT01787500
Phase 1
Completed
33 patients
Medications:
Cetuximab
Vemurafenib
This phase I trial studies the side effects and best dose of vemurafenib when given together with cetuximab and irinotecan hydrochloride in treating patients with solid tumors that have spread to other parts of the body or cannot be removed by surger...
United States
NCT01791309
Phase 1
Completed
16 patients
Medications:
Vemurafenib
The purpose of this study is to test a new drug combination consisting of two drugs, vemurafenib (also known as ZelborafTM) and panitumumab (also known as VectibixTM). This treatment is being tested in a subgroup of patients with colorectal cancer wh...
United States